Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Nanopore SARS-CoV-2 Sequencing Test Gets CE Mark

NEW YORK – Oxford Nanopore Technologies said on Friday that its LamPore SARS-CoV-2 sequencing test has obtained the CE mark for use with the GridIon platform.

The assay, which combines loop-mediated isotheral amplification (LAMP) with nanopore sequencing and can run on the GridIon and MinIon Mk1C platforms, targets the ORF1a, E, and N genes of the virus. Last month, researchers in the UK published a preprint of a validation study involving around 500 clinical samples, showing that the test is highly reproducible and has a sensitivity of 99.1 percent and a specificity of 99.6 percent.

Oxford Nanopore is rolling the LamPore test out globally, initially in the UK, Germany, Switzerland, and the United Arab Emirates, according to a company statement.

It is also pursuing regulatory approvals in other countries, including Emergency Use Authorization in the US and, in collaboration with G42, authorization in the United Arab Emirates.

The Scan

UK Moves to Allow Sale of Gene-Edited Food

The UK is moving ahead to allow the sale of gene-edited food in England, Scotland, and Wales, according to New Scientist.

Questions for the Field

Stat News writes that the alleged Buffalo shooter's citation of genetics research raises questions about what the field can do.

Cell Studies on Tumor Evolution in Mouse Model of Lung Cancer, Stereo-seq, Bacteriophage Responses

In Cell this week: tumor evolution tracked in mouse model of lung cancer, organogenesis mapped using Stereo-seq, and more.

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.